Targeting of c-MET and AXL by cabozantinib is a potential therapeutic strategy for patients with head and neck cell carcinoma

Local or metastatic relapse following surgery, radiotherapy, and cisplatin is the leading cause of death in patients with head and neck squamous cell carcinoma (HNSCC). Our study shows overexpression of c-MET and AXL in HNSCC cells and patients resistant to radiotherapy and cisplatin. We demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagege, Anais, Saada-Bouzid, Esma, Ambrosetti, Damien, Rastoin, Olivia, Boyer, Julien, He, Xingkang, Rousset, Julie, Montemagno, Christopher, Doyen, Jérome, Pedeutour, Florence, Parola, Julien, Bourget, Isabelle, Luciano, Frederic, Bozec, Alexandre, Cao, Yihai, Pagès, Gilles, Dufies, Maeva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512663/
https://www.ncbi.nlm.nih.gov/pubmed/36130479
http://dx.doi.org/10.1016/j.xcrm.2022.100659

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9512663/
https://www.ncbi.nlm.nih.gov/pubmed/36130479
http://dx.doi.org/10.1016/j.xcrm.2022.100659

Ejemplares similares